Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
Physical activity declines after starting GLP-1 obesity treatments
Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which…
SMOC1 gene plays a surprising role in the development of type 2 diabetes
Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in…
Study shows prediabetes remission does not always require weight loss
New evidence shows that restoring normal glucose regulation can shield against diabetes even without weight loss, reshaping prevention…
Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use
New genetic evidence suggests that targeting GIPR and GLP1R could reduce harmful drinking patterns while improving liver and…
Metformin’s blood sugar control starts in the brain, not just the liver, study finds
Scientists uncover how low-dose metformin targets brain pathways to lower blood sugar, opening fresh avenues for safer and…
Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers
A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 medications, revealing what…